SARS-CoV-2 3CLpro-IN-6 

SARS-CoV-2 3CLpro-IN-6 is a reversible covalent inhibitor of SARS-CoV-2 3CL protease. SARS-CoV-2 3CLpro-IN-6 has potent inhibitory activity for SARS-CoV-2 3CL^pro with an IC₅₀ value of 4.9 μM. SARS-CoV-2 3CLpro-IN-6 can be used for the research of coronavirus disease 2019 (COVID-19)^[1].

IC50: 4.9 μM (SARS-CoV-2 3CL^pro)^[1]

SARS-CoV-2 3CLpro-IN-6 (Compound 13) (0-100 μM) has potent inhibitory activity for SARS-CoV-2 3CL^pro with IC₅₀ value of 4.9 μM^[1].
SARS-CoV-2 3CLpro-IN-6 (5, 10 μM) has typical covalent inhibition behavior with time-dependent activity^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

405.36

C₂₂H₁₅NO₇

302821-53-0

COC(C(/C(C(C1=CC=CC=C1)=O)=C\C2=CC=C(O2)C3=C(C=CC=C3)[N+]([O-])=O)=O)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Liying Wang, et al. Discovery of novel SARS-CoV-2 3CL protease covalent inhibitors using deep learning-based screen. Eur J Med Chem. 2022 Dec 15;244:114803.  [Content Brief]